famotidine has been researched along with Zollinger-Ellison Syndrome in 16 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Zollinger-Ellison Syndrome: A syndrome that is characterized by the triad of severe PEPTIC ULCER, hypersecretion of GASTRIC ACID, and GASTRIN-producing tumors of the PANCREAS or other tissue (GASTRINOMA). This syndrome may be sporadic or be associated with MULTIPLE ENDOCRINE NEOPLASIA TYPE 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ability of famotidine to control gastric acid hypersecretion in 32 patients with Zollinger-Ellison syndrome was compared to that of cimetidine or ranitidine." | 9.06 | Famotidine: effective treatment of Zollinger-Ellison syndrome. ( Gardner, JD; Howard, JM; Jensen, RT; Maton, PN; Vinayek, R; Wank, SA, 1987) |
| "Famotidine, a new, potent, long-acting histamine H2-receptor antagonist was compared with cimetidine and ranitidine in 9 patients with Zollinger-Ellison syndrome." | 7.67 | Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. ( Cherner, JA; Chremos, AN; Ciarleglio, CA; Collen, MJ; Cornelius, MJ; Gardner, JD; Howard, JM; Jensen, RT; Maton, PN; McArthur, KE, 1985) |
| "Famotidine is a new histamine H2-receptor antagonist." | 6.37 | Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. ( Campoli-Richards, DM; Clissold, SP, 1986) |
| "Omeprazole 60 mg/day was administered to these 8 patients; after one month, the dose was reduced to 40 mg/day, and after another month to 20 mg/day." | 5.29 | Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients. ( Annibale, B; Cassetta, MR; Corleto, V; D'Ambra, G; Delle Fave, G; Ferrua, B; Saggioro, A, 1993) |
| " Pentagastrin was infused continuously in healthy subjects as a model for patients with Zollinger-Ellison syndrome." | 5.09 | Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study. ( Martin, P; McKeand, W; Ohning, G; Paul, J; Pisegna, JR; Walsh, JH, 1999) |
| "The histamine (H2)-receptor antagonist famotidine was compared with ranitidine and cimetidine in its ability to control gastric acid hypersecretion in 33 patients with gastric hypersecretory states (32 patients with Zollinger-Ellison syndrome and one patient with idiopathic hypersecretion)." | 5.06 | Famotidine in the therapy of gastric hypersecretory states. ( Gardner, JD; Howard, JM; Jensen, RT; Maton, PN; Slaff, JI; Vinayek, R; Wank, SA, 1986) |
| "The ability of famotidine to control gastric acid hypersecretion in 32 patients with Zollinger-Ellison syndrome was compared to that of cimetidine or ranitidine." | 5.06 | Famotidine: effective treatment of Zollinger-Ellison syndrome. ( Gardner, JD; Howard, JM; Jensen, RT; Maton, PN; Vinayek, R; Wank, SA, 1987) |
| "Several histamine H2 receptor antagonists and the H+,K(+)-ATPase inhibitor, omeprazole, have been shown to be capable of controlling gastric acid secretion safely and effectively in patients with Zollinger-Ellison syndrome." | 4.77 | Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. ( Gardner, JD; Jensen, RT; Maton, PN, 1989) |
| "Famotidine, a new, potent, long-acting histamine H2-receptor antagonist was compared with cimetidine and ranitidine in 9 patients with Zollinger-Ellison syndrome." | 3.67 | Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. ( Cherner, JA; Chremos, AN; Ciarleglio, CA; Collen, MJ; Cornelius, MJ; Gardner, JD; Howard, JM; Jensen, RT; Maton, PN; McArthur, KE, 1985) |
| "Famotidine is a new histamine H2-receptor antagonist." | 2.37 | Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. ( Campoli-Richards, DM; Clissold, SP, 1986) |
| "Omeprazole 60 mg/day was administered to these 8 patients; after one month, the dose was reduced to 40 mg/day, and after another month to 20 mg/day." | 1.29 | Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients. ( Annibale, B; Cassetta, MR; Corleto, V; D'Ambra, G; Delle Fave, G; Ferrua, B; Saggioro, A, 1993) |
| "Famotidine is a potent H2 receptor antagonist containing a thiazole ring structure, thus differing chemically from cimetidine and ranitidine." | 1.27 | Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology. ( , 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (56.25) | 18.7374 |
| 1990's | 7 (43.75) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dammann, HG | 1 |
| Müller, P | 1 |
| Simon, B | 1 |
| Kommerell, B | 1 |
| Shiratori, K | 1 |
| Watanabe, S | 1 |
| Maruyama, M | 1 |
| Adachi, H | 1 |
| Itoh, Y | 1 |
| Kurokawa, K | 1 |
| Takeuchi, T | 1 |
| Kanakia, RR | 1 |
| Sawant, PD | 1 |
| Nanivadekar, SA | 1 |
| Vishwanath, N | 1 |
| Rajagopalan, K | 1 |
| Shroff, CP | 1 |
| Vinayek, R | 4 |
| Hahne, WF | 1 |
| Euler, AR | 1 |
| Norton, JA | 2 |
| Jensen, RT | 7 |
| Corleto, V | 1 |
| Annibale, B | 1 |
| D'Ambra, G | 1 |
| Saggioro, A | 1 |
| Ferrua, B | 1 |
| Cassetta, MR | 1 |
| Delle Fave, G | 1 |
| Pisegna, JR | 2 |
| Martin, P | 1 |
| McKeand, W | 1 |
| Ohning, G | 1 |
| Walsh, JH | 1 |
| Paul, J | 1 |
| Slimak, GG | 1 |
| Metz, DC | 1 |
| Maton, PN | 6 |
| Gardner, JD | 6 |
| Nechaĭ, AI | 1 |
| Kalinin, AP | 1 |
| Trofimov, VT | 1 |
| Howard, TJ | 1 |
| Passaro, E | 1 |
| Howard, JM | 3 |
| Chremos, AN | 1 |
| Collen, MJ | 1 |
| McArthur, KE | 1 |
| Cherner, JA | 1 |
| Ciarleglio, CA | 1 |
| Cornelius, MJ | 1 |
| Campoli-Richards, DM | 1 |
| Clissold, SP | 1 |
| Wank, SA | 3 |
| Slaff, JI | 1 |
| Frucht, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diagnostic Evaluation of Patients With Suspected Abnormalities of Gastric Secretion[NCT00001240] | 0 participants | Observational | 1989-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for famotidine and Zollinger-Ellison Syndrome
| Article | Year |
|---|---|
[Gastrin-producing neoformations (Zollinger-Ellison syndrome)].
Topics: Adult; Aged; Child; Cimetidine; Diagnosis, Differential; Famotidine; Gastrectomy; Gastrins; Humans; | 1990 |
The current status of the surgical and medical treatment of the Zollinger-Ellison syndrome.
Topics: Anti-Ulcer Agents; Cimetidine; Famotidine; Humans; Prospective Studies; Ranitidine; Zollinger-Elliso | 1990 |
Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Topics: Cimetidine; Famotidine; Gastric Acid; Histamine H2 Antagonists; Humans; Nizatidine; Omeprazole; Para | 1989 |
Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
Topics: Animals; Famotidine; Histamine H2 Antagonists; Humans; Kinetics; Peptic Ulcer; Thiazoles; Zollinger- | 1986 |
4 trials available for famotidine and Zollinger-Ellison Syndrome
| Article | Year |
|---|---|
Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Dose- | 1999 |
Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.
Topics: Adult; Aged; Cimetidine; Dose-Response Relationship, Drug; Duodenal Neoplasms; Famotidine; Female; F | 1992 |
Famotidine in the therapy of gastric hypersecretory states.
Topics: Adult; Aged; Cimetidine; Clinical Trials as Topic; Drug Therapy, Combination; Famotidine; Female; Ga | 1986 |
Famotidine: effective treatment of Zollinger-Ellison syndrome.
Topics: Adult; Aged; Cimetidine; Dose-Response Relationship, Drug; Famotidine; Female; Gastric Acid; Histami | 1987 |
8 other studies available for famotidine and Zollinger-Ellison Syndrome
| Article | Year |
|---|---|
[24-hour intragastric acid profile in a ZES patient with H2 blockers].
Topics: Adult; Drug Administration Schedule; Famotidine; Female; Gastric Acid; Gastric Acidity Determination | 1984 |
[A case of refractory chronic Zollinger-Ellison syndrome--treated successfully with famotidine].
Topics: Chronic Disease; Esophageal Diseases; Esophagogastric Junction; Famotidine; Histamine H2 Antagonists | 1984 |
Primary gastrinoma of the liver.
Topics: Child; Famotidine; Gastrinoma; Humans; Jejunostomy; Liver Neoplasms; Male; Zollinger-Ellison Syndrom | 1994 |
Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Topics: Administration, Oral; Cimetidine; Dose-Response Relationship, Drug; Famotidine; Female; Gastric Acid | 1993 |
Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients.
Topics: Adult; Drug Administration Schedule; Famotidine; Female; Gastric Acid; Humans; Male; Middle Aged; Om | 1993 |
Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
Topics: Aged; Cimetidine; Delayed-Action Preparations; Famotidine; Histamine H2 Antagonists; Humans; Middle | 1985 |
Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
Topics: Duodenal Ulcer; Famotidine; Gastric Acid; Histamine H2 Antagonists; Humans; Recurrence; Stomach Ulce | 1987 |
Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study.
Topics: Adolescent; Adult; Aged; Famotidine; Female; Gastrectomy; Gastric Acid; Humans; Male; Middle Aged; P | 1988 |